Skip to content
Triangle logo TriangleGet started
← Full study record

NCT04099277 · OUTCOME

PK: Cmax of LY3435151 in Combination With Pembrolizumab

A Study of LY3435151 in Participants With Solid Tumors · Source last updated 2021-08-31

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
Not reported
Unit
Not reported
Interval / dispersion
Not reported
Time frame
Predose Cycle 1 Day 1 through Predose Cycle 5 Day 1 (21 Day Cycles)

What was measured

PK: Cmax of LY3435151 in Combination with Pembrolizumab.

Analysis population: Zero participants were analyzed. The study was terminated early and no data was collected.

Groups in this outcome

10 mg LY3435151

Participants received 10 mg dose of LY3435151 via intravenous (IV) as an IV push or IV bolus infusion.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
10 mg LY34351510

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields
denoms
  1. counts
    1. group Id
      OG000
      value
      0
    units
    Participants
description
PK: Cmax of LY3435151 in Combination with Pembrolizumab.
groups
  1. description
    Participants received 10 mg dose of LY3435151 via intravenous (IV) as an IV push or IV bolus infusion.
    id
    OG000
    title
    10 mg LY3435151
population Description
Zero participants were analyzed. The study was terminated early and no data was collected.
reporting Status
POSTED
time Frame
Predose Cycle 1 Day 1 through Predose Cycle 5 Day 1 (21 Day Cycles)
title
PK: Cmax of LY3435151 in Combination With Pembrolizumab
type
SECONDARY

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice